Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levodopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.70 |
| ▸ | RECQL | P46063 | 6/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.70 |
| ▸ | USP2 | O75604 | 4/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.70 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.70 |
| ▸ | FYN | P06241 | 3/20 | 0.70 |
| ▸ | LCK | P06239 | 3/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | HTR2A | P28223 | 2/20 | 0.70 |
| ▸ | EGFR | P00533 | 2/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | KDM6B | O15054 | 1/20 | 0.62 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levodopa SCHEMBL2688586 | 0.86 | TDP1 (0.60) | KDM4EHSD17B10TDP1RECQLALOX15 | |
| Levodopa SCHEMBL18960587 | 0.86 | TDP1 (0.60) | KDM4EHSD17B10TDP1RECQLALOX15 | |
| Levodopa SCHEMBL18960581 | 0.86 | TDP1 (0.60) | KDM4EHSD17B10TDP1RECQLALOX15 | |
| Levodopa SCHEMBL18960582 | 0.85 | TDP1 (0.58) | KDM4EHSD17B10TDP1RECQLALOX15 | |
| Levodopa SCHEMBL18960584 | 0.85 | TDP1 (0.58) | KDM4EHSD17B10TDP1RECQLALOX15 | |
| Levodopa SCHEMBL4202261 | 0.85 | TDP1 (0.58) | KDM4EHSD17B10TDP1RECQLALOX15 | |
| Levodopa SCHEMBL4202289 | 0.85 | TDP1 (0.58) | KDM4EHSD17B10TDP1RECQLALOX15 | |
| Levodopa SCHEMBL18960583 | 0.85 | TDP1 (0.58) | KDM4EHSD17B10TDP1RECQLALOX15 | |
| Levodopa SCHEMBL31017988 | 0.85 | TDP1 (0.58) | KDM4EHSD17B10TDP1RECQLALOX15 | |
| SCHEMBL4200437 | 0.83 | KDM4E (0.57) | KDM4EHSD17B10TDP1RECQLALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047529-A1 | METHODS OF INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2022-02-17 | — | — | US | claimed |
| EP-3849533-A1 | METHODS OF INHIBITION | University of Canberra (AU) | 2021-07-21 | — | — | EP | claimed |
| WO-2020051648-A1 | METHODS OF INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2020-03-19 | — | — | WO | claimed |
| EP-3101001-A1 | DEUTERATED CATECHOLAMINE DERIVATIVES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | ratiopharm GmbH (DE) | 2016-12-07 | — | — | EP | claimed |
| US-20090018191-A1 | Deuterated Catecholamine Derivatives and Medicaments Comprising Said Compounds | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2009-01-15 | — | — | US | claimed |
| US-20220047529-A1 | METHODS OF INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2022-02-17 | — | — | US | disclosed |
| EP-3849533-A1 | METHODS OF INHIBITION | University of Canberra (AU) | 2021-07-21 | — | — | EP | disclosed |
| EP-3101001-B1 | DEUTERATED CATECHOLAMINE DERIVATIVES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | TEVA PHARMACEUTICALS INT GMBH (CH) | 2020-04-01 | — | — | EP | disclosed |
| WO-2020051648-A1 | METHODS OF INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2020-03-19 | — | — | WO | disclosed |
| US-RE46555-E1 | Deuterated catecholamine derivatives and medicaments comprising said compounds | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-09-19 | — | — | US | disclosed |
| EP-3101001-A1 | DEUTERATED CATECHOLAMINE DERIVATIVES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | ratiopharm GmbH (DE) | 2016-12-07 | — | — | EP | disclosed |
| US-8247603-B2 | Deuterated catecholamine derivatives and medicaments comprising said compounds | BIRDS PHARMA GMBH BEROLINA INNOVATIVE (DE) | 2012-08-21 | — | — | US | disclosed |
| US-20090018191-A1 | Deuterated Catecholamine Derivatives and Medicaments Comprising Said Compounds | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2009-01-15 | — | — | US | disclosed |
| EP-1991522-A2 | DEUTERATED CATECHOLAMINE DERIVATIVES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | Birds Pharma GmbH Berolina Innovative Research & Development Services (DE) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007093450-A2 | DEUTERATED CATECHOLAMINE DERIVATIVES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BIRDS PHARMA GMBH BEROLINA INNOVATIVE RESEARCH & DEVELOPMENT SERVICES (DE) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018191-A1 | Deuterated Catecholamine Derivatives and Medicaments Comprising Said Compounds | COMT, DDT, TYR | DRD3 62/4885KDM4E 1504/4885HSD17B10 419/4885 |
| US-20220047529-A1 | METHODS OF INHIBITION | SLC6A3, DBH, SNCA | DRD3 7/4885KDM4E 1444/4885HSD17B10 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.